Related Experiment Video
Updated: May 31, 2026

In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease
Published on: July 19, 2024
Gut microbiota and pediatric metabolic dysfunction-associated steatotic liver disease: clinical evidence and
Bhagyalakshmi Nair1, Adithya Jayaprakash Kamath1, Aswathy R Devan1
1Department of Pharmacognosy, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi, India.
Abstract:
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously referred to as Non-alcoholic fatty liver disease (NAFLD), is among the most common chronic liver conditions globally. The incidence of MASLD has been rising, primarily due to lifestyle changes, excessive calorie intake, and other metabolic conditions like obesity and Type 2 diabetes mellitus in both adults and children. An inclusive understanding of risk factors of childhood MASLD is still unknown. Based on the limited case studies published, familial clustering is prominent in MASLD suggesting role of genetic factors. Moreover, children with MASLD are at higher risk of obesity, diabetes and hypertension. Studies associating the colonic microbiome with MASLD have been limited and complicated by inconsistencies in study design and approach but mostly indicate a role in the pediatric population. The present review provides a comprehensive understanding of the most recent clinical studies (2013-2026) on the role of gut microbiome in the development of pediatric MASLD.
Related Concept Videos
Microbiota Modulation by Antibiotics
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Dysbiosis of the Gut Microbiota
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Gut-Brain Axis
Inborn Errors of Metabolism
